Results 41 to 50 of about 29,662,057 (278)
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Biomolecules, 2022 Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is)
Francesca Romana Prandi +8 more
doaj +1 more source
Российский кардиологический журнал, 2021 The development of chronic kidney disease (CKD) is a risk factor not only for cardiovascular diseases, but also for heart failure (HF). This article is a literary review on the use of Sodium-glucose co-transporter-2 (NGLT2) inhibitors in patients with ...
M. M. Batyushin
doaj +1 more source
Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis [PDF]
, 2023 As a novel widely used drug, sodium-glucose co-transporter (SGLT) 2 inhibitor may lower blood glucose in type 2 diabetics through blocking SGLT2 to curtain glucose reabsorption in proximal renal tubular cells.
Xiao-qi Wang +5 more
core +1 more source
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential [PDF]
Cardiovascular Drugs and Therapy, 2020 AbstractSodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D). However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)–related events and cardiovascular mortality.
Brito, Dulce +9 more
openaire +3 more sources
Apical and basolateral localisation of GLUT2 transporters in human lung epithelial cells [PDF]
, 2008 Glucose concentrations of normal human airway surface liquid are approximately 12.5 times lower than blood glucose concentrations indicating that glucose uptake by epithelial cells may play a role in maintaining lung glucose homeostasis.
Baines, DL +15 more
core +1 more source
, 2014 Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options. Unlike previously available agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin ...
Joshua J Neumiller
core +1 more source
Frontiers in Pharmacology, 2022 Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors play a key role in the treatment of type 2 diabetes mellitus.
Chen Li +7 more
doaj +1 more source
Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
European Heart Journal Supplements, 2022 Abstract The 2021 guidelines of the European Society of Cardiology on the diagnosis and therapy of heart failure (HF) introduced relevant changes in the pharmacological treatment of chronic HF. Among these, certainly the most significant was the introduction in the therapeutic flow-chart (with the highest recommendation level) of the ...
Cice, Gennaro +2 more
openaire +2 more sources
FEBS Letters, EarlyView.Animals must match their growth rate to available nutrients. We show that in Drosophila larvae, the nutrient‐sensing TOR kinase controls growth by regulating levels of TFAM, a key regulator of mitochondrial function, in the adipose tissue. When nutrients are abundant, high TOR activity suppresses TFAM, lowering mitochondrial bioenergetic activity and ...
Shrivani Sriskanthadevan‐Pirahas +4 more
wiley +1 more source
Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
Journal of Education, Health and Sport, 2022 Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in ...
Marcin Czarkowski +3 more
doaj +1 more source